Health
American Factories Lag in Adopting A.I. This Drugmaker Is an Exception.
In a sterile Bristol Myers Squibb lab about an hour north of Boston, scientists in scrubs and hairnets transfer living cells to a 2,000-liter stainless steel bioreactor that grows them for weeks. The goal is to produce proteins that are genetically engineered to attack cells that cause disease.
Tiny variations in heat, light or pH level can stop the cells from growing, causing drug shortages that endanger patients. Typically scientists would have to wait to see what went wrong during that fragile process, but now artificial intelligence is used to carefully monitor important variables — such as temperature and oxygen levels — and alert technicians if there are problems.
Every year the World Economic Forum and McKinsey recognize manufacturers that are on the cutting edge of technology, including artificial intelligence. This year, the Bristol Myers Squibb facility in Devens, Mass., was the only manufacturer in the United States that made the list of 23.
While American companies typically lead in artificial intelligence research and capital investment, U.S. manufacturers often struggle to translate those breakthroughs into productivity gains on the factory floor.
Of the 223 factories that have made the World Economic Forum’s Global Lighthouse Network list since 2018, 14 have been in the United States, while 99 are in China. Of the American ones, four are in the pharmaceutical and life sciences sector.
“China is scaling faster,” said Rahul Shahani, a partner at McKinsey who works with the World Economic Forum on the initiative. He added, “They have technologists in the factories — hundreds of them — while in the U.S. we’re competing for that same talent with Silicon Valley.”
Large American pharmaceutical companies have been a rare bright spot in the use of A.I. Many drugmakers, including Pfizer and Eli Lilly, are investing billions in A.I. and related technologies to accelerate drug discovery and streamline manufacturing. The trend coincides with President Trump’s demands that drugmakers produce more drugs on U.S. soil.
Scientists at the Devens facility use artificial intelligence to discover molecules that can target cancer and other diseases with greater precision. A.I. can comb through data sets from past experiments to identify possibilities that a human might not have considered. Researchers then test those molecules in the virtual world — a process referred to as “in silico.” Only the most promising are tested in a physical laboratory. The company can run multiple “in silico” experiments at a time.
“Drug discovery and bio-manufacturing are definitely areas where A.I. can have the most impact,” said Kyle Chan, a fellow at the Brookings Institution’s John L. Thornton China Center. “These are areas where A.I. has some of the largest advantages over previous approaches given the need to process and synthesize large, complex data sets.”
Still, there’s no guarantee that technological advantages will instantly equate to benefits for patients. The history of drug development is filled with failures, and it is unknown whether molecules identified by A.I. will pass muster in clinical trials.
The Bristol Myers Squibb facility sits on an 89-acre campus where buildings are decorated with portraits of cancer survivors..
Previously, scientists and technicians were never sure why some batches of cells produced a large amount of proteins, while others failed completely. But now A.I. uses information from past batches to identify what variables need to change. For example, if oxygen levels are lower than previous batches, the system will suggest that oxygen be added. If the pH levels are higher than previous batches, it will recommend a fix. It also makes suggestions about the best time to harvest the cells.
These innovations have boosted the volume of drugs produced for clinical trials and commercial use at the facility by about 40 percent, according to a company spokeswoman.
“We are able to now intervene in the batches during the manufacturing process and not have to wait until we get to the end,” said Karin Shanahan, executive vice president, chief supply chain and operations officer for the company.
These innovations have helped stabilize production of Orencia, a drug that treats autoimmune conditions such as rheumatoid arthritis using cells that are extremely difficult to grow. In 2024, manufacturing challenges resulted in a shortage in some parts of the world.
The company is just beginning to use A.I. in its manufacturing process of another drug, Breyanzi, which turns a cancer patient’s own white blood cells into a personalized therapy. Currently, the Devens plant is authorized by the Food and Drug Administration to produce treatments for just 12 patients at a time.
Ms. Shanahan said she hoped that eventually A.I. would increase production of the treatment, often viewed as a last resort for people with blood cancers such as leukemia.
Bristol Myers Squibb has embarked on a series of cost-cutting measures as the key patent for its cancer drug Opdivo expires in 2028. The drug, which uses proteins that have been genetically engineered to target cancer cells, generated more than $10 billion of the company’s $48 billion in revenue last year.
The company is trimming $2 billion in costs by the end of 2027 in addition to $1.5 billion in cuts announced in 2024. More than 1,000 positions are being eliminated, many of them at a research facility in Lawrenceville, N.J., heightening anxiety about A.I.’s taking jobs away in the sector.
At the Semafor World Economy summit last month, Bristol Myers Squibb’s chief executive, Chris Boerner, said the company had a responsibility to use A.I. to further its mission but acknowledged that it could adversely affect some employees.
“We are engaging with those employees to make them more marketable around this technology — with the company or elsewhere,” he said.
The facility in Devens, which was completed in 2009 at a cost of $750 million, wasn’t designed with A.I. in mind. As recently as 2020, employees used Excel spreadsheets for some tasks. Batch records that document every step of production were filled out by hand. But in recent years, the company has prioritized digitizing and automating its processes.
“We needed to make sure that we could formulate our products faster, that we could commercially scale them faster,” Ms. Shanahan said. “And so that’s really what forced us to start to go down that path.”
Overall the company aims to cut the time it takes to bring a drug to market to about six years, from nine, she said.
Other factories that received recognition from the World Economic Forum this year included Yueda Textile in Yancheng, China, which collects sensor data to detect machine maintenance issues before they occur, reducing costs; and Midea, a manufacturer of microwaves and air-conditioners in Thailand that uses A.I. to investigate customer complaints, generating recommendations for corrective action that cut resolution time from months to days.
NEWYou can now listen to Fox News articles!
The American Cancer Society (ACS) has updated its guidelines for colorectal cancer screening.
The organization released the update in its flagship journal on Wednesday, noting that the new recommendations “re-affirm” that adults at average risk should be screened for colorectal cancer at age 45 and continue through 75, for those with a life expectancy greater than 10 years.
In addition to the standard colonoscopy, the ACS also recommends that patients receive a blood-based screening test in a doctor’s office, which is designed to detect tumor DNA in the blood.
COMMON CANCER TYPE COULD BE DETECTED WITH NEW BLOOD TEST
The ACS also suggested an at-home screening option that looks for hidden blood and molecular markers in stool samples.
These new guidelines reflect recent advancements in disease detection, as well as a “critical shift in public health strategy to expand screening options and lower barriers to access,” the ACS stated in a press release.
The ACS recommends blood-based testing and at-home stool sampling as options for colorectal cancer screening. (iStock)
Dr. Robert Smith, senior vice president of early cancer detection science at the American Cancer Society and senior author of the report, wrote in a statement that colorectal cancer should be emphasized as a “highly preventable disease as much as a treatable one.”
“By offering more screening tools in our guideline update, more eligible adults will be able to participate in lifesaving colorectal cancer testing, helping to close the screening gap and catch more cancers at an earlier, treatable stage,” he added.
JAMES VAN DER BEEK MISTOOK CANCER SYMPTOMS FOR PROBLEMS WITH HIS DIET
According to the ACS, colorectal screening “dramatically improves survival,” as studies show early-stage detection yields a five-year survival rate of more than 90% in the U.S.
About one in three American adults are eligible for colorectal cancer screening but have not been tested, although ACS research marks colorectal cancer as the top cancer killer of adults under 50.
Colorectal cancer is the top cancer killer of adults under the age of 50, according to the ACS. (iStock)
People at a high risk of colorectal cancer may need to begin screening before age 45 or be screened more often, the ACS added. Those over 85 years old should no longer be screened for colorectal cancer, per the guidelines.
Dr. William Dahut, chief scientific officer at the ACS, commented that “no matter which test you choose, what’s most important is to get screened, and that includes underserved, rural and minority populations.”
CLICK HERE FOR MORE HEALTH STORIES
These guideline changes follow a surge in colorectal cancer diagnoses in younger individuals. Recent ACS research revealed a 50% relative increase in diagnoses in adults aged 45 to 49 from 2021 to 2022.
Dr. Aparna Parikh, medical director of the Center for Young Adult Colorectal Cancer at the Mass General Cancer Center, who is not affiliated with the ACS, shared that experts don’t “entirely understand why” cases are on the rise.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“But it seems to be an interplay of a person’s risk factors, overall makeup and early exposures,” she previously told Fox News Digital. “[Those] include dietary exposures, environmental exposures and possible antibiotic exposures, as well as lifestyle factors in the right host.”
Changes in bowel habits are the primary red flag that should raise the suspicion of colorectal cancer. (iStock)
Another recent ACS study found that drinking heavily and consistently over an adult’s lifetime could lead to a higher risk of colorectal cancer.
Other known risk factors include family history, obesity, smoking, a diet high in red and processed meats, inflammatory bowel disease, and a personal history or family history of polyps.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
While there may be no symptoms of colorectal cancer before diagnosis, especially in the early stages, certain symptoms should not be overlooked, experts say.
Dr. Eitan Friedman, PhD, an oncologist and founder of The Suzanne Levy-Gertner Oncogenetics Unit at the Sheba Medical Center in Israel, confirmed to Fox News Digital that changes in bowel habits are the primary red flag that should raise the suspicion of colorectal cancer.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Other symptoms include fatigue as a result of anemia, stomach pain or abdominal discomfort, rectal bleeding or blood in the stool, weakness and unexplained weight loss.
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
NEWYou can now listen to Fox News articles!
The sudden death of Kyle Busch has drawn attention to a rare but devastating medical progression: when pneumonia escalates into fatal sepsis.
An ER doctor spoke with Fox News Digital about how sepsis can trigger a rapid health decline.
“Sepsis is actually not a specific disease or diagnosis, but rather the syndrome that occurs when the body has certain abnormal findings and a presumed infection,” said Dr. Kenneth J. Perry, a South Carolina-based emergency medicine physician.
HOW PNEUMONIA PROGRESSES TO SEPSIS: DOCTORS EXPLAIN AFTER KYLE BUSCH’S DEATH
The markers of sepsis include elevated white blood cell counts, a high or low temperature, and elevated heart and respiratory rates, according to Perry. Because of this, a patient with pneumonia is often already technically septic by definition.
In the wake of Kyle Busch’s sudden passing, there is a focus on the rapid decline from pneumonia to fatal sepsis. (Getty; iStock)
While many people assume a worsening infection means bacteria are multiplying uncontrollably, it often has more to do with the body’s internal environment.
“It is often not the bacteria itself that is causing the specific decline,” Perry said. “In most cases, it is a cascade of inflammatory processes that are set in motion by the infection.”
When this inflammation spirals out of control, the body moves from having a manageable infection into severe sepsis. This is when otherwise healthy people can rapidly deteriorate.
SURGE IN WALKING PNEUMONIA AFFECTS THESE HIGH-RISK GROUPS, SAYS DR. MARC SIEGEL
“The concerning thing that can happen with any individual … is that sepsis can then lead to low blood pressure, worsening vital signs and organ damage,” Perry said.
“As multiple organs fail, it becomes very difficult for the medical team to treat and can sometimes lead ultimately to death.”
“The medical evaluation provided to the Busch Family concluded that severe pneumonia progressed into sepsis, resulting in rapid and overwhelming associated complications,” the family shared in a statement. (James Gilbert/Getty Images)
It is very unlikely to have pneumonia and not have any symptoms, according to Perry. Early signs can mimic a severe flu, including fevers, chills, a productive cough, and chest or back pain in cases where the lung is infected.
When sepsis begins to take hold, time becomes the most critical factor. “We have known for a number of years that early antibiotic therapy is beneficial in the treatment of sepsis,” Perry said.
CLICK HERE FOR MORE HEALTH STORIES
If you or a loved one are managing an infection at home, the doctor says the following red flags mean you should bypass the clinic and head straight to the emergency room.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
- Shortness of breath or difficulty breathing
- A racing heart rate or fever that continues to worsen even after starting treatment
- Severe chest pain associated with a productive cough
The slide into sepsis is, in most cases, a cascade of inflammatory processes that are set in motion by the infection, the doctor said. (iStock)
While cases like Busch’s are tragic, Perry stressed that this shouldn’t cause widespread panic. Most patients with pneumonia do very well with standard oral antibiotics.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The NASCAR star’s rapid decline underscores the importance of medical vigilance and “having a primary care physician with whom you have a good relationship,” according to the ER doctor.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“Monitoring symptoms while having easy access to primary care is a very beneficial and appropriate plan for most patients,” he added.
-
Los Angeles, Ca1 hour agoLoved ones search for 80-year-old woman missing in Westlake for nearly a week
-
Detroit, MI2 hours agoDetroit PWHL team names Michigan native Josh Sciba head coach
-
San Francisco, CA2 hours agoWorld Cup dining guide near Levi’s Stadium and in San Francisco
-
Dallas, TX2 hours agoNorth Texas doughnut shops named among best in U.S.
-
Miami, FL2 hours agoMiami’s Jai Lucas Tackles Year Two With A New Roster and New Goal
-
Boston, MA2 hours agoA look inside Joan Bennett Kennedy’s Back Bay condo, listed for $2.6m
-
Denver, CO2 hours agoDenver Fashion Week Responds To Community Demand With Second Model Audition Date – 303 Magazine
-
Seattle, WA2 hours agoThe Sale Of The Seattle Seahawks Gets A Big News Update
